Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.89, $0.20 better than the analyst estimate of $0.69. Revenue for the quarter came in at $178 million versus the consensus estimate of $173.52 million.

GUIDANCE:

Pacira Pharma sees FY2024 revenue of $680-705 million, versus the consensus of $695.4 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT
• MSCI upgrades Bulgaria to Frontier, flags Indonesia and Turkey risks